Experts Questioned Complement Inhibitors for Eye Disease

Eye specialists debated whether these treatments provide meaningful benefits for patients with geographic atrophy.

Updated on Oct. 12, 2026 in Alzheimer’s

Experts Questioned Complement Inhibitors for Eye Disease

Live Poll

Do you believe medical treatments are worth potential side effects over lifestyle-based alternatives?

At the 2026 American Academy of Ophthalmology annual meeting, experts gathered to debate the clinical value of complement inhibitors like pegcetacoplan and avacincaptad pegol. During the session, physicians expressed significant skepticism regarding whether these therapies effectively alter outcomes for patients with geographic atrophy.

Why it matters

This debate highlights ongoing professional uncertainty about the real-world utility of newer treatments for this condition. For patients and their physicians, it underscores the importance of balancing potential progression-slowing benefits against known risks.

Clinical trials indicate complement inhibitors slow geographic atrophy progression by 21%, while the Age-Related Eye Disease Study 1 and 2 showed progression reductions of 36% and 35% respectively. Researchers noted that one in 4,000 injections of these inhibitors is linked to vasculitis.

The players

American Academy of Ophthalmology

The professional medical association representing eye physicians and surgeons who oversee clinical standards for vision health.

The details

Complement inhibitors are administered through monthly injections intended to slow the degeneration associated with geographic atrophy. While these agents target specific pathways to potentially stabilize the condition, 63% of US physicians remain uncertain about their benefits. The risk of vasculitis, an inflammation of the blood vessels, occurs at a rate of one in every 4,000 injections.

October 2026: Experts debated complement inhibitors at the AAO annual meeting.

Health Landscape

This debate follows in the tradition of the Age-Related Eye Disease Study by evaluating new interventions against established standards for retinal health. The discussion marks a departure from standard clinical adoption as physicians weigh these new pharmacological agents against proven nutritional protocols.

If you are receiving or considering complement inhibitors for geographic atrophy, this debate highlights the importance of discussing the expected clinical benefits and risks with your eye specialist. It is worth asking your doctor about how these treatments compare to established preventive strategies.

The takeaway

While new treatments for geographic atrophy have reached the market, significant questions remain about their effectiveness and safety profiles among the medical community. Always review the latest clinical consensus and potential side effects like vasculitis with your physician during your eye exams.